Kirsten Fischer
MD
Professor of Hematology
👥Biography 个人简介
Kirsten Fischer at Cologne co-led the CLL14 trial demonstrating fixed-duration venetoclax plus obinutuzumab as superior to chlorambucil plus obinutuzumab in previously untreated CLL, establishing the first fixed-duration chemo-free regimen in first-line CLL. The concept of fixed-duration treatment (rather than continuous therapy) with venetoclax-based regimens is a practice-changing advance with quality-of-life and resistance-prevention benefits.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Kirsten Fischer 的研究动态
Follow Kirsten Fischer's research updates
留下邮箱，当我们发布与 Kirsten Fischer（University Hospital Cologne）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment